Oxcia AB is developing novel drugs within the DNA damage and repair (DDR) platform.
The two main projects, karonudib (MTH1 inhibitor) and OGG1 inhibitor originates from work performed at Karolinska Institutet and extensive pre-clinical research has been done in collaboration with national and international prominent universities and institutes.    

Karonudib is presently investigated in two on-ongoing clinical phase 1 trials in solid and hematological cancers, performed at Karolinska University Hospital.

OGG1 inhibitor project is in lead optimisation stage and preclinical proof of concept has been obtained in lung fibrosis and NASH disease models.